ZA200203367B - Antidiabetic formulation and method. - Google Patents

Antidiabetic formulation and method.

Info

Publication number
ZA200203367B
ZA200203367B ZA200203367A ZA200203367A ZA200203367B ZA 200203367 B ZA200203367 B ZA 200203367B ZA 200203367 A ZA200203367 A ZA 200203367A ZA 200203367 A ZA200203367 A ZA 200203367A ZA 200203367 B ZA200203367 B ZA 200203367B
Authority
ZA
South Africa
Prior art keywords
antidiabetic
formulation
antidiabetic formulation
Prior art date
Application number
ZA200203367A
Other languages
English (en)
Inventor
Beth Anne Piper
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23716278&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200203367(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of ZA200203367B publication Critical patent/ZA200203367B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ZA200203367A 1999-11-03 2002-04-26 Antidiabetic formulation and method. ZA200203367B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/432,465 US6586438B2 (en) 1999-11-03 1999-11-03 Antidiabetic formulation and method

Publications (1)

Publication Number Publication Date
ZA200203367B true ZA200203367B (en) 2003-09-10

Family

ID=23716278

Family Applications (2)

Application Number Title Priority Date Filing Date
ZA200203367A ZA200203367B (en) 1999-11-03 2002-04-26 Antidiabetic formulation and method.
ZA200203368A ZA200203368B (en) 1999-11-03 2002-04-26 Pharmaceutical composition comprising a combination of metformin and glibenclamide.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ZA200203368A ZA200203368B (en) 1999-11-03 2002-04-26 Pharmaceutical composition comprising a combination of metformin and glibenclamide.

Country Status (34)

Country Link
US (2) US6586438B2 (cs)
EP (1) EP1253944A2 (cs)
JP (2) JP2003529551A (cs)
KR (2) KR20020050253A (cs)
CN (3) CN101273981B (cs)
AR (1) AR026355A1 (cs)
AU (1) AU781781B2 (cs)
BG (2) BG65850B1 (cs)
BR (1) BR0015295A (cs)
CA (1) CA2389931A1 (cs)
CZ (2) CZ304090B6 (cs)
DE (1) DE60038455T2 (cs)
EE (1) EE05210B1 (cs)
ES (1) ES2302702T3 (cs)
GE (2) GEP20053538B (cs)
HK (1) HK1045655A1 (cs)
HU (1) HUP0300642A3 (cs)
IL (3) IL149138A0 (cs)
LT (1) LT5025B (cs)
LV (1) LV12907B (cs)
MX (1) MXPA02004290A (cs)
MY (2) MY125118A (cs)
NO (1) NO20022086L (cs)
NZ (1) NZ552074A (cs)
PL (1) PL366112A1 (cs)
RO (1) RO123109B1 (cs)
RU (1) RU2276604C2 (cs)
SK (1) SK4992002A3 (cs)
TN (2) TNSN00206A1 (cs)
TW (1) TWI241185B (cs)
UA (2) UA75583C2 (cs)
UY (1) UY26425A1 (cs)
WO (1) WO2001032158A2 (cs)
ZA (2) ZA200203367B (cs)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235627B2 (en) * 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
US20030040469A1 (en) * 2000-03-08 2003-02-27 Knudsen Liselotte Bjerre Lowering serum lipids
HUP0300325A3 (en) * 2000-03-17 2004-08-30 Ajinomoto Kk Drugs for complications of diabetes and neuropathy and utilization thereof and their preparation
FR2816840B1 (fr) 2000-11-17 2004-04-09 Flamel Tech Sa Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation
US7062312B2 (en) * 2001-01-17 2006-06-13 Pediamed Pharmaceuticals, Inc. Combination and method including a visual marker for determining compliance with a medication regimen
US20020187926A1 (en) * 2001-03-07 2002-12-12 Knudsen Liselotte Bjerre Combined use of derivatives of GLP-1 analogs and PPAR ligands
US20030022816A1 (en) * 2001-03-07 2003-01-30 Knudsen Liselotte Bjerre Combined use of derivatives of GLP-1 analogs and PPAR ligands
FR2825023B1 (fr) * 2001-05-23 2005-04-15 Flamel Tech Sa Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif
KR20040044992A (ko) * 2001-09-28 2004-05-31 썬 파마슈티컬 인더스트리스 리미티드 당뇨병 치료용 투여형태
US6924311B2 (en) * 2001-10-17 2005-08-02 X-Ceptor Therapeutics, Inc. Methods for affecting various diseases utilizing LXR compounds
US7183321B2 (en) * 2001-12-17 2007-02-27 Bristol-Myers Squibb Company Antidiabetic formulation and method
PT1482919E (pt) 2002-01-25 2007-07-25 Silanes Sa De Cv Lab Composição farmacêutica que é utilizada para controlar a glucose no sangue de doentes com diabetes de tipo 2.
CN100553625C (zh) 2002-04-09 2009-10-28 弗拉梅技术公司 活性成分微囊的口服混悬液
AU2002356419A1 (en) 2002-06-17 2003-12-31 Themis Laboratories Private Limited Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them
AU2003243929B2 (en) * 2002-07-04 2009-06-04 Zp Holding Spv K/S GLP-1 and methods for treating diabetes
JP2004067575A (ja) * 2002-08-06 2004-03-04 Yaizu Suisankagaku Industry Co Ltd 糖尿病治療薬効果促進剤
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
SE526943C2 (sv) * 2002-08-26 2005-11-22 Indevex Ab Födoämneskompositionsprodukt
UA80991C2 (en) 2002-10-07 2007-11-26 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
US20040147564A1 (en) * 2003-01-29 2004-07-29 Rao Vinay U. Combinations of glimepiride and the thiazolidinedione for treatment of diabetes
ATE457166T1 (de) * 2003-07-24 2010-02-15 Wockhardt Ltd Orale zusammensetzungen zur behandlung von diabetes
DK1648933T3 (da) * 2003-07-25 2009-09-07 Conjuchem Biotechnologies Inc Langvarige insulinderivater og fremgangsm der
US20050202063A1 (en) * 2003-08-26 2005-09-15 Ebn International Kft Food product
WO2005065654A2 (en) * 2003-12-31 2005-07-21 Alpharma, Inc. Rosiglitazone formulations
WO2005065663A1 (en) * 2003-12-31 2005-07-21 Alpharma, Inc. Rosiglitazone and metformin formulations
EP1746993A4 (en) * 2004-04-29 2007-08-29 Andrx Labs Llc METFORMIN COMPOSITIONS WITH CONTROLLED RELEASE
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
KR100760430B1 (ko) * 2004-12-31 2007-10-04 한미약품 주식회사 당뇨병 치료제의 경구 투여용 서방성 복합 제제 및 이의제조 방법
WO2006074278A2 (en) * 2005-01-05 2006-07-13 Mitsunori Ono Compositions for treating diabetes or obesity
WO2006080524A1 (ja) * 2005-01-31 2006-08-03 Ajinomoto Co., Inc. 血糖降下剤を含有する、耐糖能異常、境界型糖尿病、インスリン抵抗性及び高インスリン血症の改善ないし治療用医薬組成物
EP1889618A4 (en) * 2005-05-27 2010-11-24 Daiichi Sankyo Co Ltd COMBINED MEDICATION FOR THE TREATMENT OF DIABETES
RU2308265C2 (ru) * 2005-07-25 2007-10-20 Илья Николаевич Медведев Способ выбора лечения тромбоцитопатии при метаболическом синдроме
WO2007070355A2 (en) * 2005-12-09 2007-06-21 Metaproteomics, Llc Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes
JP5094416B2 (ja) * 2005-12-28 2012-12-12 武田薬品工業株式会社 糖尿病治療剤
FR2896157B1 (fr) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
NZ573360A (en) 2006-05-04 2012-08-31 Boehringer Ingelheim Int Polymorphic forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine
WO2008011713A1 (en) * 2006-07-26 2008-01-31 Diamedica Inc. Methods of diagnosis and treatment for metabolic disorders
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
US20100136561A1 (en) * 2008-05-16 2010-06-03 Interleukin Genetics, Inc. Genetic Markers for Weight Management and Methods of Use Thereof
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
KR101189639B1 (ko) * 2008-12-15 2012-10-12 씨제이제일제당 (주) 메트포르민 및 α-글리코시다제 억제제를 포함하는 경구 제제 및 그 제조방법
EP3222277B1 (en) 2009-03-31 2020-02-26 Ligand Pharmaceuticals Inc. A biphenylsulfonamide endothelin and angiotensin ii receptor antagonist to treat glomerulosclerosis and iga-induced nephropathy
AU2010241567B2 (en) 2009-04-29 2013-10-31 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising EPA and a cardiovascular agent and methods of using the same
HUE051916T2 (hu) 2009-04-29 2021-04-28 Amarin Pharmaceuticals Ie Ltd Stabil gyógyászati készítmény és annak alkalmazási módszerei
US8455472B2 (en) 2009-06-15 2013-06-04 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
BR112012012641A2 (pt) 2009-11-27 2020-08-11 Boehringer Ingelheim International Gmbh TRATAMENTO DE PACIENTES DIABÉTICOS GENOTIPADOS COM INIBIDORES DE DPP-lVTAL COMO LINAGLIPTINA
CN101810628B (zh) * 2010-04-13 2012-05-23 北京四环科宝制药有限公司 二甲双胍格列吡嗪片及其制备方法
CN103003300B (zh) 2010-04-27 2017-06-09 西兰制药公司 Glp‑1受体激动剂和胃泌素的肽缀合物及其用途
NZ602921A (en) 2010-05-05 2016-01-29 Boehringer Ingelheim Int Combination therapy comprising the administration of a glp-1 receptor agonist and a ddp-4 inhibitor
PT2568988T (pt) 2010-05-11 2016-09-22 Janssen Pharmaceutica Nv Formulações farmacêuticas compreendendo derivados de 1-(beta-d-glucopiranosil)-2-tienilmetilbenzeno como inhibidoras de sglt
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
NZ712068A (en) 2010-11-29 2017-03-31 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
WO2012090225A2 (en) * 2010-12-29 2012-07-05 Nutracryst Therapeutics Private Limited Novel cocrystals / molecular salts of metformin with oleoylethanolamide as an effective anti-diabetic + anti- obesity agent
US9572784B2 (en) 2011-01-07 2017-02-21 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
US8796338B2 (en) 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
US9480663B2 (en) 2011-01-07 2016-11-01 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
CA2823397C (en) 2011-01-07 2020-03-10 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
KR20140100947A (ko) 2011-11-03 2014-08-18 질랜드 파마 에이/에스 Ｇｌｐ-1 수용체 효능제 펩타이드 가스트린 접합체들
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
MX379226B (es) 2012-01-06 2025-03-11 Anji Pharma Us Llc Composiciones y métodos para tratar trastornos metabólicos.
CN104254325A (zh) 2012-01-06 2014-12-31 埃尔舍利克斯治疗公司 双胍组合物和治疗代谢性病症的方法
WO2013115742A1 (en) * 2012-01-31 2013-08-08 Mahmut Bilgic Pharmaceutical composition comprising alpha-glucosidase inhibitor
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
ES2929025T3 (es) 2012-05-14 2022-11-24 Boehringer Ingelheim Int Linagliptina, un derivado de xantina como inhibidor de dpp-4, para su uso en el tratamiento del SRIS y/o de la septicemia
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US20130315891A1 (en) 2012-05-25 2013-11-28 Matthew Charles Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
PL2854841T3 (pl) 2012-06-04 2017-08-31 Diamedica Inc. Izoformy glikozylacji ludzkiej kalikreiny tkankowej 1
IN2015DN00544A (cs) 2012-07-23 2015-06-26 Zealand Pharma As
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
KR101336499B1 (ko) * 2013-03-06 2013-12-03 씨제이제일제당 (주) 당뇨병의 예방 또는 치료용 복합 조성물
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
PT3057984T (pt) 2013-10-17 2018-10-24 Boehringer Ingelheim Int Análogos de glucagon acilados
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
KR102310392B1 (ko) 2013-11-06 2021-10-13 질랜드 파마 에이/에스 글루카곤-ｇｌｐ-1-ｇｉｐ 삼원 효능제 화합물
JP6682432B2 (ja) 2013-11-06 2020-04-15 ジーランド ファーマ アクティーゼルスカブ Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法
JP6615109B2 (ja) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ−４阻害薬の医学的使用
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
JP6898231B6 (ja) 2014-10-29 2021-07-28 ジーランド ファーマ アクティーゼルスカブ Ｇｉｐアゴニスト化合物及び方法
DK3283507T3 (da) 2015-04-16 2020-01-02 Zealand Pharma As Acyleret glucagonanalog
JP2019517542A (ja) 2016-06-10 2019-06-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング リナグリプチンおよびメトホルミンの組合せ
KR102502040B1 (ko) 2016-12-09 2023-02-24 질랜드 파마 에이/에스 아실화 glp-1/glp-2 이중 효능제
KR20190122706A (ko) 2017-03-09 2019-10-30 다이어메디카 인코포레이티드 조직 칼리크레인 1의 투약 형태
EP3675882A4 (en) 2017-08-30 2021-07-28 Pendulum Therapeutics, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS
AU2019349678A1 (en) * 2018-09-24 2021-04-15 Pendulum Therapeutics, Inc. Microbial compositions and methods of use
LT4056176T (lt) 2018-09-24 2024-08-12 Amarin Pharmaceuticals Ireland Limited Nepalankių subjekto širdies ir kraujagyslių reiškinių rizikos sumažinimo būdai
JP2022554020A (ja) 2019-11-12 2022-12-27 アマリン ファーマシューティカルズ アイルランド リミテッド 心房細動および／または心房粗動を患う対象における心血管イベントのリスクを低減する方法
CN113648318B (zh) * 2020-05-12 2023-08-25 中国科学院上海营养与健康研究所 增强细胞产热和治疗疾病的应用
WO2022225896A1 (en) 2021-04-21 2022-10-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
US4060634A (en) 1973-09-26 1977-11-29 Boehringer Mannheim G.M.B.H. Rapidly resorbable glibenclamide
DE2348334C2 (de) 1973-09-26 1982-11-11 Boehringer Mannheim Gmbh, 6800 Mannheim Neue Zubereitungsform des N-4-[2-(5-Chlor-2-methoxybenzamido)äthyl]- phenyl-sulfonyl-N'-cyclohexylharnstoffs
NO154918C (no) 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
EP0062704A1 (de) 1980-12-03 1982-10-20 Hoechst Aktiengesellschaft Cyclopropancarbonsäureester-derivate als Mittel zum Bekämpfen von Magendasseln bei Equiden
JPS6051189A (ja) 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
US4916163A (en) 1985-06-04 1990-04-10 The Upjohn Company Spray-dried lactose formulation of micronized glyburide
DE3543999A1 (de) 1985-12-13 1987-06-19 Bayer Ag Hochreine acarbose
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
DE3833439A1 (de) 1988-10-01 1991-09-12 Hoechst Ag Verfahren zur mikronisierung von glibenclamid
US5258185A (en) * 1989-08-23 1993-11-02 Bauer Kurt H Highly active, rapidly absorbable formulations of glibenclamide, processes for the production thereof and their use
DK36392D0 (da) 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
DE4323636A1 (de) 1993-07-15 1995-01-19 Hoechst Ag Arzneistoffzubereitungen aus umhüllten, schwerstwasserlöslichen Arzneistoffen für Inhalationsarzneiformen und Verfahren zu ihrer Herstellung
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
IT1276130B1 (it) 1995-11-14 1997-10-27 Gentili Ist Spa Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
US6153632A (en) 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
WO1998055107A1 (en) * 1997-06-06 1998-12-10 Depomed, Inc. Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
ATE201139T1 (de) 1997-06-13 2001-06-15 Novo Nordisk As Neue dosierung für diabetes type 2
ID23372A (id) 1997-06-18 2000-04-20 Smithkline Beecham Plc Pengobatan diabetes dengan tiazolidindion dan metformin
GB9715306D0 (en) 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
IL135673A0 (en) 1997-10-17 2001-05-20 Aventis Pharm Prod Inc Therapeutic uses of quinoline derivatives
ATE261935T1 (de) 1997-12-08 2004-04-15 Bristol Myers Squibb Co Neue metformin salze und verfahren
FR2774591B1 (fr) 1998-02-12 2000-05-05 Lipha Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie
FI111167B (fi) * 1998-02-24 2003-06-13 Kemira Chemicals Oy Menetelmä lietteen säilyvyyden parantamiseksi
JP2002508162A (ja) 1998-02-27 2002-03-19 ノボ ノルディスク アクティーゼルスカブ Ｎ末端を短縮したｇｌｐ−１誘導体
PT974356E (pt) 1998-07-15 2004-02-27 Merck Sante Sas Comprimidos compreendendo uma combinacao de metformina e de glibenclamida
NZ510207A (en) 1998-09-17 2003-08-29 Bristol Myers Squibb Co Method for treating atherosclerosis employing an aP2 inhibitor
AR028299A1 (es) 1999-09-17 2003-05-07 Novartis Ag Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes.
EP2620443A1 (en) 2012-01-25 2013-07-31 Galecto Biotech AB Novel galactoside inhibitors of galectins

Also Published As

Publication number Publication date
DE60038455D1 (de) 2008-05-08
CZ304090B6 (cs) 2013-10-16
GEP20053539B (en) 2005-06-10
ZA200203368B (en) 2003-09-02
KR20020050253A (ko) 2002-06-26
EE200200241A (et) 2003-12-15
CN100386114C (zh) 2008-05-07
US7598262B2 (en) 2009-10-06
HUP0300642A3 (en) 2006-05-29
KR20020057994A (ko) 2002-07-12
US20020177602A1 (en) 2002-11-28
SK4992002A3 (en) 2003-04-01
BR0015295A (pt) 2003-06-24
AU8022900A (en) 2001-05-14
IL149139A (en) 2011-11-30
MY125118A (en) 2006-07-31
EE05210B1 (et) 2009-10-15
LT2002062A (en) 2003-03-25
TNSN00206A1 (en) 2005-11-10
MXPA02004290A (es) 2003-02-12
UA75583C2 (uk) 2006-05-15
MY136636A (en) 2008-11-28
LV12907B (en) 2003-08-20
DE60038455T2 (de) 2009-04-23
HK1045655A1 (zh) 2002-12-06
UA76706C2 (uk) 2006-09-15
CA2389931A1 (en) 2001-05-10
HUP0300642A2 (hu) 2003-07-28
UY26425A1 (es) 2001-07-31
CN102283853A (zh) 2011-12-21
JP2003529551A (ja) 2003-10-07
BG106732A (bg) 2003-02-28
IL149138A (en) 2007-12-03
CZ20021547A3 (cs) 2003-01-15
WO2001032158A3 (en) 2002-08-29
RU2002113764A (ru) 2004-03-20
NO20022086L (no) 2002-06-24
IL149138A0 (en) 2002-11-10
CN1414862A (zh) 2003-04-30
TWI241185B (en) 2005-10-11
KR100769786B1 (ko) 2007-10-24
NZ552074A (en) 2008-06-30
BG106733A (bg) 2003-02-28
PL366112A1 (en) 2005-01-24
JP2013028631A (ja) 2013-02-07
RO123109B1 (ro) 2010-11-30
AR026355A1 (es) 2003-02-05
US20020183345A1 (en) 2002-12-05
US6586438B2 (en) 2003-07-01
RU2276604C2 (ru) 2006-05-20
CN101273981B (zh) 2011-01-26
LT5025B (lt) 2003-06-25
WO2001032158A2 (en) 2001-05-10
TNSN00207A1 (en) 2005-11-10
EP1253944A2 (en) 2002-11-06
AU781781B2 (en) 2005-06-16
NO20022086D0 (no) 2002-05-02
GEP20053538B (en) 2005-06-10
CN101273981A (zh) 2008-10-01
BG65850B1 (bg) 2010-03-31
ES2302702T3 (es) 2008-08-01

Similar Documents

Publication Publication Date Title
ZA200203367B (en) Antidiabetic formulation and method.
ZA200108217B (en) Application apparatus and method.
ZA200203316B (en) New use and novel n-azabicyclo-amide derivatives.
EP1455793A4 (en) ANTI-DIABETAL FORMULATION AND METHOD
ZA200201816B (en) A vaccine composition and method of using the same.
EG24226A (en) Formulation
AU1029501A (en) Cleaning-in-place composition and method for using the same
AU6635800A (en) Pyridomorphinans, thienomoprhinans and use thereof
GB9902304D0 (en) Formulation
GB9905898D0 (en) Controlled-dose formulation
ZA200006340B (en) Dhea composition and method.
IL145220A0 (en) Stabilized composition based on pyridinyl-sulfinyl-benzimidazoles and process
AU1755301A (en) Rollercross-type game and method thereof
GB9927614D0 (en) Sterliant formulation
HUP0203678A3 (en) Nitro-sulfobenzamide-derivatives, preparation and use thereof
AU5979300A (en) Angiopoietin-6 and uses thereof
ZA994697B (en) Pharmaceutical formulation.
AU4652399A (en) Drawing method and drawing device
ZA995262B (en) Massage composition and method.
GB9927812D0 (en) Improved pesticide formulation
ZA200005868B (en) Construction method and elements. Construction method and elements.
AUPQ040299A0 (en) Formulation and method
AU5744799A (en) Direct printing device and method
AU1701600A (en) Direct printing device and method
GB9902236D0 (en) Formulation